Report Library
All Reports
2019 JP Morgan Conference Preview
January 04, 2019
The 37th annual JP Morgan Healthcare Conference is being held in San Francisco, CA from January 7-10, 2019. Surprises are not
uncommon at JP Morgan and companies do not typically preannounce what they will be presenting, but our analysts have selected a
number of companies to watch throughout the week to prime you for the jam-packed meeting. Here we summarize the current affairs
surrounding these companies and potential discussion points to be presented. We have also included a graph of drug companies presenting at JP Morgan with the greatest number of large impact catalysts expected in 2019.
Stay tuned for Biomedtracker and Meddevicetracker's full real-time coverage of the 2019 JP Morgan Healthcare Conference. Our daily reports published each evening will bring you the important pipeline updates and key takeaways from the entire day’s presentations. With our platforms helping you navigate along the way, you’ll stay informed on the latest updates in drug development and not miss a beat from the biggest investor healthcare conference of the year.
Companies highlighted in this preview:
For our disclosures, please read the Biomedtracker Research Standards.
Stay tuned for Biomedtracker and Meddevicetracker's full real-time coverage of the 2019 JP Morgan Healthcare Conference. Our daily reports published each evening will bring you the important pipeline updates and key takeaways from the entire day’s presentations. With our platforms helping you navigate along the way, you’ll stay informed on the latest updates in drug development and not miss a beat from the biggest investor healthcare conference of the year.
Companies highlighted in this preview:
- AbbVie
- Acadia Pharmaceuticals
- Acorda Therapeutics
- Alkermes
- Alnylan Pharmaceuticals
- AMAG Pharmaceuticals
- Amarin Corp
- Amgen
- Amicus Therapeutics
- AnaptysBio
- Aptinyx
- Ascendis Pharma
- Audentes Therapeutics
- AVEO Pharmaceuticals
- BioMarin Pharmaceutical
- Bristol Myers Squibb
- Celgene
- Dexcom
- Dova Pharmaceuticals
- Dynavax Technologies
- Edwards lifesciences
- Galapagos NV
- Gilead
- GW Pharmaceuticals
- Halozyme Therapeutics
- Idera Pharmaceuticals
- Insulet Corporation
- Intercept Pharmaceuticals
- Intra-Cellular Therapies
- Ionis Pharmaceuticals
- Ipsen SA
- Ironwood Pharmaceutials
- Jazz Pharmaceuticals
- Jounce Therapeutics
- Karyopharm Therapeutics
- Lexicon Pharmaceuticals
- Medtronic
- Merck KgaA
- Moderna
- Myokardia
- Nektar Therapeutics
- Novartis
- Novavax
- Pfizer
- PTC Therapeutics
- Puma Biotechnology
- Sage Therapeutics
- Sangamo Therapeutics
- Sanofi
- Sarepta Therapeutics
- Seattle Genetics
- Solid Biosciences
- Spark Therapeutics
- Supernus
- Tricida
- UCB S.A
- Ultragenyx Pharmaceutical
- Vertex Pharmaceuticals
- Zimmer Biomet Holdings
For our disclosures, please read the Biomedtracker Research Standards.
| Disease Group Covered: |
Allergy
Autoimmune/immunology Cardiovascular Dermatology Endocrine ENT/Dental Gastroenterology (Non Inflammatory Bowel Disease) Hematology Infectious Disease Metabolic Neurology Not Specified Obstetrics/Gynecology Oncology Ophthalmology Orthopedics Psychiatry Renal Respiratory Rheumatology (Non Autoimmune) Urology |
Additional Resources: